01life key facts
as of Oct 2026- Developer of gut microorganisms drugs designed for disease prevention and treatment.
- 01life is valued at approximately $181.8M as of Oct 2026 (last reported valuation).
- It has raised $14.5M; the latest was Later Stage VC in Mar 2025.
- Notable investors include Green Pine Capital Partners, Empower Investment, Beyond Ventures, Danen Capital, Resources Investment — 7 tracked in total.
- Status: Privately Held (backing).
01life's last reported valuation, Apr 2023. Nothing priced has surfaced since.
- ·Watch 01life: the Monday email on marks, rounds and moves
01life funding rounds
No funding rounds for 01life are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
01life valuation
01life's last reported valuation was $182 million in Apr 2023. No priced round, secondary trade or fund mark has surfaced since.
01life investors
7 investors are on record for 01life, including Green Pine Capital Partners, Empower Investment, Beyond Ventures and Danen Capital.
About 01life
Developer of gut microorganisms drugs designed for disease prevention and treatment. The company develops original new drug pipelines, genetic testing products, and probiotics+ products based on its complete life-cycle micro-ecological health management services with periodic examination and intervention, enabling customers with innovative human flora genetic testing products for more visibility into microecological health.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2016
- Employees
- 20
- Website
- indiv.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.